Russell B Van Dyke

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. pmc A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Infect Dis 54:285-93. 2012
  2. ncbi request reprint Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Pediatrics 109:e61. 2002
  3. doi request reprint Mother-to-child transmission of HIV-1 in the era prior to the availability of combination antiretroviral therapy: the role of drugs of abuse
    Russell B Van Dyke
    Tulane University Health Sciences, New Orleans, LA 70112, United States
    Life Sci 88:922-5. 2011
  4. pmc Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA, USA
    J Acquir Immune Defic Syndr 57:165-73. 2011
  5. pmc Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    J Infect Dis 198:1599-608. 2008
  6. doi request reprint Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment
    Paige L Williams
    aCenter for Biostatistics in AIDS Research bDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts cDepartment of Pediatrics Infectious Diseases, University of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado dTulane University School of Medicine, New Orleans, Louisiana eEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland fDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts gSection of Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana hDepartment of Pediatrics, University of Colorado School of Medicine, Denver, Colorado iNew York University School of Medicine, New York jDepartment of Pediatrics, New Jersey Medical School, Newark, New Jersey kSaban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    AIDS 27:1959-70. 2013
  7. doi request reprint Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study
    Steven E Lipshultz
    Department of Pediatrics, Universityof Miami Leonard M Miller School of Medicine, FL, USA
    JAMA Pediatr 167:520-7. 2013
  8. doi request reprint Bone mineral density in children and adolescents with perinatal HIV infection
    Linda A DiMeglio
    Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
    AIDS 27:211-20. 2013
  9. ncbi request reprint Balance and gait abnormalities of a child with West Nile virus infection
    Troy D Moon
    Department of Pediatric Infectious Diseases, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Pediatr Infect Dis J 24:568-70. 2005
  10. pmc Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants
    Patricia A Sirois
    Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Pediatr Infect Dis J 32:648-55. 2013

Research Grants

  1. TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT
    Russell Van Dyke; Fiscal Year: 2006
  2. Tulane/LSU HIV/AIDS Clinical Trials Networks Unit
    Russell Van Dyke; Fiscal Year: 2007
  3. Coordinating Center for the Pediatric HIV/AIDS Cohort S*
    Russell Van Dyke; Fiscal Year: 2007

Detail Information

Publications16

  1. pmc A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Infect Dis 54:285-93. 2012
    ..We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance...
  2. ncbi request reprint Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Pediatrics 109:e61. 2002
    ..Little is known about the adherence of children to HAART. The objective of this study was to identify correlates of adherence to HAART and the relationship between adherence and study outcomes in a pediatric clinical trial...
  3. doi request reprint Mother-to-child transmission of HIV-1 in the era prior to the availability of combination antiretroviral therapy: the role of drugs of abuse
    Russell B Van Dyke
    Tulane University Health Sciences, New Orleans, LA 70112, United States
    Life Sci 88:922-5. 2011
    ..Reasons for this association may be both behavioral and biological. Drug use is associated with poor adherence to ART and medical care. Opioids enhance infection of macrophages by HIV...
  4. pmc Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA, USA
    J Acquir Immune Defic Syndr 57:165-73. 2011
    ..We sought to describe the disease status of a large cohort of such children and identify predictors of their current CD4 count and HIV viral load (VL)...
  5. pmc Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    J Infect Dis 198:1599-608. 2008
    ..Human immunodeficiency virus (HIV) therapy includes a backbone of nucleoside reverse-transcriptase inhibitors (NRTIs). Toxicities associated with NRTIs are not fully defined in children...
  6. doi request reprint Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment
    Paige L Williams
    aCenter for Biostatistics in AIDS Research bDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts cDepartment of Pediatrics Infectious Diseases, University of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado dTulane University School of Medicine, New Orleans, Louisiana eEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland fDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts gSection of Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana hDepartment of Pediatrics, University of Colorado School of Medicine, Denver, Colorado iNew York University School of Medicine, New York jDepartment of Pediatrics, New Jersey Medical School, Newark, New Jersey kSaban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    AIDS 27:1959-70. 2013
    ..To evaluate associations of perinatal HIV infection, HIV disease severity, and combination antiretroviral treatment with age at pubertal onset...
  7. doi request reprint Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study
    Steven E Lipshultz
    Department of Pediatrics, Universityof Miami Leonard M Miller School of Medicine, FL, USA
    JAMA Pediatr 167:520-7. 2013
    ..This study suggests that highly active ART (HAART) does not appear to impair heart function...
  8. doi request reprint Bone mineral density in children and adolescents with perinatal HIV infection
    Linda A DiMeglio
    Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
    AIDS 27:211-20. 2013
    ..To estimate prevalence of low bone mineral density (BMD) in perinatally HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) children, and to determine predictors of BMD in HIV+...
  9. ncbi request reprint Balance and gait abnormalities of a child with West Nile virus infection
    Troy D Moon
    Department of Pediatric Infectious Diseases, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Pediatr Infect Dis J 24:568-70. 2005
    ..West Nile virus-specific IgM and IgG antibodies were detected in the patient's cerebrospinal fluid...
  10. pmc Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants
    Patricia A Sirois
    Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Pediatr Infect Dis J 32:648-55. 2013
    ..This study evaluated effects of perinatal exposure to antiretroviral (ARV) medications on neurodevelopment of HIV-exposed, uninfected infants...
  11. pmc Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old
    Myron J Levin
    Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO, USA
    J Acquir Immune Defic Syndr 55:197-204. 2010
    ..Quadrivalent human papillomavirus vaccine (QHPV) is > 95% effective in preventing infection with vaccine-type human papillomavirus. The safety and immunogenicity of QHPV are unknown in HIV-infected children...
  12. pmc Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era
    Sharon A Nachman
    Department of Pediatrics, Stony Brook University Medical Center, Stony Brook, NY 11794 8111, USA
    Arch Pediatr Adolesc Med 163:164-71. 2009
    ....
  13. ncbi request reprint Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies
    Heather B Jaspan
    Interdisciplinary Program in Molecular and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    J Clin Virol 31:190-7. 2004
    ..Natural protective mechanisms involving lentivirus-specific antibodies may therefore exist to limit in utero transmission of lentiviruses...
  14. ncbi request reprint Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol
    Susan Schuval
    Schneider Children s Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA
    Arch Pediatr Adolesc Med 158:1007-13. 2004
    ..To evaluate the prevalence of hepatitis C virus (HCV) infection in children with perinatal human immunodeficiency virus (HIV) infection...
  15. ncbi request reprint Incidence of opportunistic and other infections in HIV-infected children in the HAART era
    Philimon Gona
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Mass, USA
    JAMA 296:292-300. 2006
    ....
  16. doi request reprint Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study
    Kunjal Patel
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Infect Dis 46:507-15. 2008
    ..Given that HIV infection is chronic and that exposure to HAART is likely to be life-long, there is a need to evaluate the long-term effect of HAART on survival in this population...

Research Grants4

  1. TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT
    Russell Van Dyke; Fiscal Year: 2006
    ..Finally, we will continue to provide leadership in the areas of perinatal transmission of HIV, the complications of HIV infection, adolescent medicine, and behavioral issues such as adherence to therapy. ..
  2. Tulane/LSU HIV/AIDS Clinical Trials Networks Unit
    Russell Van Dyke; Fiscal Year: 2007
    ..The CTU will conduct clinical trials developed by the IMPAACT Network and an Adult Network in order to develop new and improved ways to treat and prevent HIV infection in adults and children. ADMINISTRATIVE COMPONENT: ..
  3. Coordinating Center for the Pediatric HIV/AIDS Cohort S*
    Russell Van Dyke; Fiscal Year: 2007
    ....